As the marijuana market continues its widespread growth, researchers remain merely at the threshold of exploring the manifold potential medical applications of cannabis.
As the marijuana market continues its widespread growth, researchers remain merely at the threshold of exploring the manifold potential medical applications of cannabis.
There's been a lot of focus lately on InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) breakthrough proprietary biosynthesis technology, and how it could unlock a $6 Billion Industry.
The cannabidiol market is large and diverse; just a few years ago, it was rather small but by 2015, consumer sales had reached $202 million, according to the CBD Report published by The Hemp Business Journal. Cannabidiol sales are expected to grow to over $2 billion by 2020.
Vancouver, Canada-based InMed Pharmaceuticals is a preclinical biotech company that specializes in developing novel drug therapies by manufacturing cannabinoids with the potential to have a therapeutic effect on specific diseases.
Marijuana is most commonly known as a combination of the dried buds found in the Cannabis Sativa plant. There are many ways of using the plant such as eating, vaporizing, smoking, brewed, and tons more, however the most common method remains smoking the plant in some sort of pipe-like device.
Through building a diversified holding base, SinglePoint, Inc. (OTC: SING) has developed from a full-service mobile technology provider to a publicly traded holding company, and its SingleSeed subsidiary is working to solve an issue that is currently plaguing legal cannabis businesses: a lack of traditional banking options.
Singlepoint, Inc. (OTC: SING) welcomed the recent request to the Financial Crimes Enforcement Network (FINCEN), by 10 senators, for further guidance ‘to financial institutions on their ability to provide services, specifically to indirect businesses that do nothing more than provide services to the state-sanctioned marijuana industry’.
As more countries begin to allow some form legalization, opportunities arise for Canadian companies to expand their business. It’s hard to ignore the fact that the boom of Canadian stocks as the country prepares for legal recreational cannabis use has been felt on a global scale.
ChineseInvestors.com, Inc. (OTCQB: CIIX) is launching a line of hemp-infused skin care products in China. The cannabinoid content of the line makes these products more than just cosmetics.
Hemp, Inc. (OTC PINK: HEMP) executives announced today that North Carolina farmers are picking up the pace in planting what they believe will be the next cash crop... industrial hemp.
Ken Clement, the founder of ABcann, with his wealth of experience and knowledge, had observed the variability in consistency and potency of cannabis that was currently available.
InMed Pharmaceuticals is making bacteria-bred cannabinoids “identical to those found in nature,” sans chemicals or even cannabis.
CBC News has learned that the Opaskwayak Cree Nation in Manitoba has taken a major stake in a medical marijuana company, with an eye to becoming a big player in the sale of pot once it becomes legal.
Algae Dynamics Corp. (OTCQB: ADYNF), a Canadian company engaged in developing proprietary research as well as products derived from cannabis and hemp oils, has commenced a collaborative relationship with Dr. Laviolette.
Shares of Canopy Growth Corp. (TSX:WEED) took a dip after reporting underwhelming fourth-quarter results that clearly didn’t impress the general public. Although the company saw Q4 revenue soar 191% year over year to $14.7 million, many analysts were looking for revenue to grow to at least $16.4 million. But that is not really a problem.